This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 814168.
CORDIS PROJECT ID 218110.
Patients and healthcare professionals have observed that feces often smell abnormal during gastrointestinal disease, thus identification of volatile organic compound (VOC) biomarkers from stool offer the potential for developing a method for rapid diagnosis of gastrointestinal diseases. Surprisingly little is known about volatile organic compounds (VOCs) found in the gut. The diagnostic and health implications of most of these compounds remain to be explored. In the GROWTH programme we aim to analyse fecal VOCs in neonates. Fecal VOC profile analysis will be conducted using this robust set-up developed by Owlstone Medical (see photo below). This odour sensing method is based on pattern recognition algorithms, mimicking the mammalian sensory system. Pilot data have shown that fecal VOC profiles could serve as an early, pre-clinical non-invasive diagnostic biomarker for necrotizing enterocolitis and neonatal sepsis. VOC profiles differed from controls up to 3 days prior to disease onset.
Tue, 22 September